Biocon has kicked off FY26 with confidence and is building momentum, setting the tone for a robust year ahead. Powered by strong gains in Biosimilars, steady growth in CRDMO, and a resilient performance in Generics, the quarter reflects more than just numbers, it's a testament to the company's ability to adapt to change and seize … Continue reading Biocon Q1FY26 Earnings is well-positioned for contined momentum and sustained growth
A Blog by Biocon 